Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome  

作　　者：Haixia Zeng Yanting Huang Dengke Liu Tianqin Xie Zheng Chen Qiulan Huang Xiaojun Zhou Xiaoyang Lai Jianping Liu 

机构地区：[1]Department of Endocrinology,Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi 330006,China [2]Department of Endocrinology,Xiangyang First People’s Hospital,Xiangyang,Hubei 441099,China [3]School of Public Health,Nanchang University,School of Public Health,Nanchang University,Nanchang,Jiangxi 330031,China

出　　处：《Chinese Medical Journal》2023年第14期1756-1758,共3页中华医学杂志（英文版）

摘　　要：To the Editor:Polycystic ovary syndrome(PCOS)is a common endocrine disorder among women of reproductive age.PCOS is characterized by infrequent or absent ovulation,high androgen levels,and hyperinsulinaemia.Androgenic excess is the main pathophysiological mechanism of the disease.Metformin can lower insulin and androgen levels,increase estradiol levels,and induce ovulation.^([1])Pioglitazone can increase the sensitivity of peripheral tissues to insulin,improve insulin resistance,reduce androgen levels,restore the menstrual cycle,and promote ovulation.^([2])Despite extensive research,the molecular mechanisms that mediate the beneficial effects of metformin or pioglitazone in the treatment of PCOS are still unclear.There are also differences in individual patient responses to drugs.

关 键 词：TABLETS AZONE DRUGS 

分 类 号：R711.75[医药卫生—妇产科学]